The company will use an exclusive license it is acquiring for a new paraben-free technology for the task.
Parabens have been used in cosmetic and pharmaceutical products since the fifties to improve shelf life and prevent bacteria.
“There is a growing concern with parabens, as they have been shown to disrupt hormone function, an effect that is linked to an increased risk of certain cancers and reproductive issues,” said Gary Thompson, M Pharma's chief executive.
They were banned in the EU in 2012, but are still used in the US.
“We are taking a two phase approach to maximizing this new proprietary technology for replacing parabens,” said Thompson.
“Phase one will be to formulate all M Pharmaceutical products to include this new parabens free technology. This will be implemented immediately following the closing of the 40J’s acquisition.
The second phase will be to out-license the parabens-free technology to other manufacturers.
M Pharma agreed to acquire Cincinnati-based 40Js at the start of January and is currently going through the due diligence process.